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Abstract The maintenance of quality of life (QoL) in
patients with high-grade glioma is an important endpoint
during treatment, particularly in those with glioblastoma
multiforme (GBM) given its dismal prognosis despite lim-
ited advances in standard therapy. It has proven difﬁcult to
identify new therapies that extend survival in patients with
recurrent GBM, so one of the primary aims of new therapies
is to reduce morbidity, restore or preserve neurologic
functions, and the capacity to perform daily activities. Apart
from temozolomide, cytotoxic chemotherapeutic agents do
not appear to signiﬁcantly impact response or survival, but
produce toxicity that is likely to negatively impact QoL.
New biological agents, such as bevacizumab, can induce a
clinically meaningful proportion of durable responses among
patientswithrecurrentGBMwithanacceptablesafetyproﬁle.
Emerging evidence suggests that bevacizumab produces an
improvement or preservation of neurocognitive function in
GBMpatients,suggestiveofQoLimprovement,inmostpoor-
prognosispatientswhowouldotherwisebeexpectedtoshowa
sudden and rapid deterioration in QoL.
Keywords Quality of life  Glioblastoma multiforme 
Bevacizumab
Introduction
High-grade gliomas, WHO grade III or IV [1, 2], are the
most common primary brain tumors in adults [1, 3]. WHO
grade IV tumors are almost exclusively (80–90%) glio-
blastoma multiforme (GBM), which are the most common
high-grade glioma (40–45%) [1, 3], the most common form
of brain tumor overall (12–15%) [1, 3], and the most
aggressive malignant primary brain tumor [4]. Despite
limited signiﬁcant advances in standard therapy, notably
temozolomide, median overall survival (OS) remains
low: 15 months for newly-diagnosed GBM [5, 6] and
5–7 monthsforrecurrent/relapsedGBM[7–10].Inaclinical
trial setting, the current standard of care (radiotherapy plus
temozolomide followed by 6 cycles of adjuvant temozolo-
mide) provided 2- and 5-year survival rates of 27 and 10%
for patients with newly diagnosed GBM [6]. Thus, an unmet
medical need for improved therapeutic options remains.
Given the poor prognosis of GBM, the primary objec-
tives of therapy are to reduce morbidity, restore or preserve
neurologic functions and the capacity to perform daily
activities as long as possible [11]. The aim of this review is
to examine the impact of GBM therapy on QoL, neuro-
cognitive function, and their correlates.
Neurocognitive functioning and QoL
It is well recognized that impairment of neurocognitive
functioning, resulting in behavioral, emotional, and
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DOI 10.1007/s11060-011-0565-xintellectual difﬁculties, occurs in nearly all patients with
brain tumors and eventually compromises their indepen-
dence [12]. This impairment is related to a combination of
various factors, including the tumor itself, tumor-related
epilepsy, treatment, and patient-related factors (e.g., age,
psychological distress) [13–16]. However, there have been
relatively few well-powered longitudinal studies of neu-
rocognitive function in patients with high-grade glioma
[17]. Neurocognitive function is an important determinant
of QoL [18–20]. Not surprisingly, neurocognitive function
assessments have been incorporated as major components
of patient assessments, along with common and widely
used questionnaires to assess health-related QoL (HR-
QoL), e.g., European Organization for Research and
Treatment of Cancer (EORTC) Core Quality of Life
Questionnaire (QLQ-C30), and Functional Assessment of
Cancer Therapy (FACT) cancer-speciﬁc scales [21].
Indeed, neurocognitive function has been shown to be a
valid predictor of long-term QoL [22–24].
As life expectancy in high-grade glioma, and particu-
larly in recurrent GBM, is so short, issues relating to QoL
are immensely important to patients and their caregivers
[17]. This is especially important in relation to new
treatments in recurrent GBM that do not yet have evi-
dence supporting their contribution to extended survival
but may signiﬁcantly delay the expected steep QoL
deterioration occurring after progression following stan-
dard therapies [17]. Unfortunately, QoL data are difﬁcult
to collect in cancer patients because they may be
unwilling to complete the questionnaire when they are
feeling unwell. Furthermore, repeated application of
lengthy, formal HR-QoL questionnaires can represent a
major and impractical burden for patients [25]. Also, the
analysis of QoL data is challenging due to the high rates
of non-random missing QoL values that may be linked to
patients’ QoL status, and if ignored may introduce bias in
the interpretation of results [26]. Interpretation of the
impact of standard and new therapies on QoL in GBM
patients is consequently problematic, even when attempt-
ing to classify their effect into the three broad categories
of negative, positive, or neutral.
To overcome these challenges, changes in neurocogni-
tive functioning may be taken as a proxy for QoL changes.
Assessment of neurocognitive function can therefore rep-
resent a practical surrogate for formal QoL assessment of
patients with recurrent GBM. In addition, besides grade
and age, performance status in patients with newly diag-
nosed glioma is an independent prognostic marker. Thus, it
is plausible to assume that neurocognitive function, irre-
spective of clinical stage, may also have prognostic
implications even after initiation of therapy and during the
course of treatment.
Treatment impact on QoL and its correlates
HR-QoL in patients with high-grade glioma has recently
been reviewed in detail [17], which noted problems asso-
ciated with interpretation of different studies and the
paucity of robust HR-QoL information derived from well-
powered randomized controlled trials. Among the seven
randomized controlled trials of new treatments published
from 2002 to 2007 they identiﬁed for high-grade glioma,
there was no or little difference between treatment groups
at baseline or follow-up evaluation. These authors sug-
gested that standard multidimensional HR-QoL question-
naires might therefore contain too many items and
consequently lack sensitivity to detect QoL changes in
patients with high-grade glioma. Simpler, practical, and
more sensitive instruments (such as cognitive function) are
therefore needed to study QoL changes in relation to
therapy in high-grade glioma, and, thus, the confounding
factor of missing substantial follow-up data (primarily
related to dropouts) needs to be addressed.
Standard therapy
Neurosurgery and/or radiotherapy are still fundamental
elements of standard therapy for patients with high-grade
glioma. It is well recognized that surgery may initially, at
least temporarily, improve QoL dramatically in a signiﬁ-
cant proportion of patients with severe symptoms related to
increased intracranial pressure [3]. Conversely, radiother-
apy may decrease QoL in some patients from adverse
effects such as hair loss, fatigue, somnolence, or cognitive
problems [26]. The inﬂuence of radiotherapy on neuro-
cognitive function has recently been reviewed [27]. It is
clear that tumor recurrence and short-term survival are
confounding variables, but it is generally agreed that short-
term memory and progression of dementia are observed in
many patients treated with brain irradiation. The impact of
adjunctive therapy with corticosteroids and antiepileptic
medication has also been extensively studied. While the
presence and severity of epileptic seizures and/or the use of
antiepileptic medication have been signiﬁcantly associated
with cognitive deﬁcits in patients with low-grade gliomas,
more so than the effects of radiotherapy [28–30], the
effects of antiepileptic medication on neurocognitive
functioning and QoL have been less extensively studied in
patients with high-grade glioma, although some studies
have reported a negative impact [31].
The negative effects of corticosteroid use on neuro-
cognitive function and/or QoL are well documented in
healthy subjects [32, 33] and in various disease states, such
as leukemia [34]. While it appears accepted that the use
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negative impact on neurocognitive function in glioma,
there would appear to be no published information in this
indication. However, it is documented that corticosteroid
use in primary brain tumors and/or metastases caused
adverse effects [35, 36] which would be expected to
decrease QoL.
Assessment of QoL is important with cytotoxic che-
motherapy, particularly when survival beneﬁt may be
marginal and has to be balanced against any negative
contribution of signiﬁcant toxicity. Among newly diag-
nosed GBM patients randomized to radiotherapy alone or
radiotherapy plus temozolomide, the addition of temozol-
omide had no signiﬁcant negative effect on QoL measures,
except on social functioning (p = 0.0052) [37]. Similarly,
among ﬁrst-relapse GBM patients, temozolomide had no
signiﬁcant negative effect on QoL, although responders to
temozolomide had improvement in most QoL domain
scores, e.g., global, motor dysfunction, emotional function,
drowsiness, future uncertainty, and communication deﬁcit,
until eventual disease progression [38–40]. These overall
ﬁndings with temozolomide in GBM are concordant with
the recent Cochrane review that evaluated randomized
controlled trial data assessing temozolomide in patients
with high-grade glioma [41].
When used as a comparator for temozolomide among
the aforementioned trials, procarbazine was reported to
have a negative impact on HR-QoL domain scores, e.g.,
drowsiness, communications deﬁcit, motor dysfunction,
role functioning, social functioning, and physical func-
tioning, regardless of disease progression status [38, 39].
The impact of combined procarbazine, CCNU (lomustine),
and vincristine (PCV) chemotherapy after radiotherapy
compared with radiotherapy alone on HR-QoL measures
was determined in the EORTC 26951 trial of patients with
anaplastic oligodendroglioma (n = 368): a major negative
impact on HR-QoL (nausea/vomiting, appetite loss, and
drowsiness) was found during and shortly after PCV
treatment [42]. However, when HR-QoL measures were
used to assess the impact of PCV chemotherapy after
radiotherapy compared with radiotherapy alone in the
Radiation Therapy Oncology Group (RTOG) trial 94-02 of
patients with mixed anaplastic oligodendroglioma, scores
were similar longitudinally and between treatments for
survivors [43]. HR-QoL (Spitzer Quality of Life Index)
score showed continual deterioration when measured lon-
gitudinally in the RTOB 98-03 study of escalating doses of
conformal three-dimensional radiation and carmustine in
GBM patients [44]. Supplementation of surgery and
radiotherapy with CCNU chemotherapy provided no ben-
eﬁt in terms of quality of life or change in clinical per-
formance [45]. Finally, there are very limited QoL data
from randomized controlled trials with implanted
carmustine-impregnated wafers in primary or recurrent
high-grade glioma according to a recent Cochrane review
[46].
New and investigational GBM therapies
Bevacizumab (Avastin
), a humanized monoclonal anti-
body that binds to and inhibits the activity of VEGF, is the
ﬁrst approved antiangiogenic cancer treatment. Bev-
acizumab acts synergistically with cytotoxic chemotherapy
or biological agents in the treatment of various tumors, e.g.,
colorectal, lung, renal, and breast cancer [47–50]. Recently,
studies in patients with recurrent high-grade glioma or
GBM have indicated promising results with durable
response using the combination of bevacizumab and iri-
notecan [51–67], and additionally in combination with
etoposide [68], nitrosourea [69], fotemustine [70], or erl-
otinib [71]. Positive results have also been reported with
single-agent bevacizumab in recurrent high-grade glioma
[57, 61, 72–74], and in combination with adjuvant tem-
ozolomide in newly diagnosed GBM [75–79].
During these studies of bevacizumab-based therapy in
high-grade glioma, it was reported that one of the conse-
quences of bevacizumab therapy is a steroid-sparing effect
in a proportion of patients, which would be expected to
positively impact QoL. Various studies have indicated a
reduction or elimination of corticosteroid use with bev-
acizumab-based therapy in patients with recurrent high-
grade glioma after prior treatment [53, 56–61, 63, 64, 73].
For example, in the randomized phase II clinical trial
comparing bevacizumab alone or in combination with iri-
notecan in 167 patients with recurrent, treatment-refractory
GBM [61], patients who were taking corticosteroids at
baseline showed a trend to take stable or decreasing doses
over time, e.g., median corticosteroid dose was reduced by
about 75% after 6 months (Fig. 1). The steroid-sparing
effect associated with bevacizumab-based therapy
appeared associated with clinical response in high-grade
glioma [58, 64] and clinical beneﬁt such as improved
neurological symptoms in high-grade glioma [59]o r
recurrent GBM [73].
A potentially positive impact of bevacizumab-based
therapy on neurocognitive function, performance status
and/or QoL has also started to emerge from reports of
clinical studies among GBM patients [52, 59, 63, 64]. For
example, in a retrospective analysis of recurrent GBM
patients treated with bevacizumab (n = 44) or without
bevacizumab (n = 79) at a single US institution [63], it
was reported that bevacizumab-treated patients took longer
to increase dexamethasone dose (median 149 vs. 130 days,
p = 0.04) and also maintained their Karnofsky Perfor-
mance Status (KPS) for longer (median 252 vs. 120 days,
p = 0.006); subgroup analysis indicated that the difference
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123in these effects were more pronounced in patients aged
[55 years. In another study of 22 consecutive patients
with recurrent GBM treated with bevacizumab plus irino-
tecan [52], cognitive function was assessed by the Blessed
Orientation-Memory-Concentration Test (BOMC) and
functional status was assessed by KPS, Barthel Index (BI),
and Instrumental Activities of Daily Living (IADL) prior to
each cycle of treatment. Improvement in BOMC score was
seen in 15 patients (62%), with median improvement of 7
points. Improvement in functional status was seen in 18
patients (85.7%), with median improvement in KPS by 10
points, BI by 8 points, and IADL by 2 points. The overall
clinical response rate with bevacizumab plus irinotecan
was 95% and was associated with signiﬁcant improvements
in cognitive functional and functional status.
Larger scale controlled clinical trials of bevacizumab-
based therapy in GBM patients were consequently under-
taken or are planned/on-going. Among these is the recently
reported BRAIN study (AVF3708g), an open-label, mul-
ticenter, randomized, phase II trial of two concurrent arms
treated with single-agent bevacizumab (n = 85) or bev-
acizumab plus irinotecan (n = 82) in patients with ﬁrst- or
second-relapse GBM who had been previously treated with
temozolomide initially or at relapse. Primary endpoint
results have been reported: estimated 6-month PFS rates
were 43 and 50% in single-agent bevacizumab and bev-
acizumab plus irinotecan arms, respectively, and objective
response rates were 28 and 38%, respectively [61]. These
results supported the activity of bevacizumab in recurrent
GBM patients given that the 6-month PFS rate was
considerably higher than the 15% rate expected for salvage
chemotherapy and/or chemotherapy alone. The authors
noted a trend for patients who were taking corticosteroids
at baseline to take stable or decreasing doses over time, but
they made no formal comparison.
More compellingly data on corticosteroid use during this
study have recently been reported [80]. At baseline, 51 and
53% of patients received systemic corticosteroids in the
single-agent bevacizumab and bevacizumab plus irinotecan
arms, respectively. More than 75 and 65% of patients in the
single-agent and combination arms, respectively, who did
not receive corticosteroids at baseline continued to receive
no corticosteroids after baseline. Sustained reduction in
corticosteroid use was deﬁned in this study as a C50% dose
reduction for C50% of time on study treatment up to
52 weeks. Among patients with complete or partial
response in the single-agent bevacizumab and bev-
acizumab plus irinotecan arms, 57 and 65%, respectively,
had a sustained reduction in corticosteroid use compared
with 17 and 38%, respectively, among those with stable or
progressive disease.
Neurocognitive function of patients treated with single-
agent bevacizumab in the BRAIN study (n = 85) has been
analyzed [81]. Patients were assessed with the Hopkins
Verbal Learning Test-Revised (HVLT-R), Trail Making
Test parts A (TMTA) and B (TMTB), and the Controlled
Oral Word Association (COWA) test. Assessments were
conducted at baseline and then every 6 weeks while
patients remained on study treatment up to 52 weeks.
Change in neurocognitive function from baseline to week 6
was categorized as improved, stable, or declined, using the
reliable change index. Between 93 and 98% of patients
completed each test at baseline and 73–78% completed
each test at both baseline and week 6. The majority of
patients demonstrated stable performance on each test at
week 6, relative to baseline. With the exception of the
COWA test, 16–28% of patients demonstrated improved
performance on one or more tests at week 6 (Table 1).
Preliminary results suggest that the majority of patients
with recurrent GBM who were treated with bevacizumab
alone in the BRAIN study demonstrated stable or improved
neurocognitive function during the ﬁrst 6 weeks of treat-
ment (81–100% across all tests). Changes across tasks and
associations with measures of clinical efﬁcacy were also
explored (Table 2).
In a recent retrospective analysis [82], 12 patients with
GBM and poor neurologic function (KPS \60%) due to
bulky disease were treated in an up-front setting with
bevacizumab following induction temozolomide in an
attempt to improve their ability to tolerate chemoradiation.
Median KPS improved from 50 to 70% and their median
dexamethasone dose was reduced from 12 to 4 mg/day.
Five of 11 evaluable patients (45%) had a partial response,
Fig. 1 Change in median corticosteroid use following treatment with
bevacizumab with or without irinotecan in patients with recurrent
glioblastoma multiforme (adapted with permission from Friedman
et al. [61])
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1234 (35%) a minor response, and 1 (10%) stable disease.
Median TTP and OS were 5.2 and 8 months, respectively.
The tumor response, rapidly improved neurologic function,
and reduced steroid requirement allowed the majority of
patients (75%) to complete deﬁnitive radiotherapy.
Little signiﬁcant information appears to have been
published on the effects of other investigational biological
agents (e.g., cilengitide, cediranib, sorafenib, sunitinib) on
corticosteroid use, neurocognitive function, or QoL in
patients with high-grade glioma or more speciﬁcally those
with GBM. In a recent phase II study of cediranib [83], an
oral pan-VEGFR tyrosine kinase inhibitor, was adminis-
tered as monotherapy (45 mg/day) in 31 patients with
recurrent GBM and resulted in encouraging proportions of
radiographic partial responses of 57 and 27% on 3- and
2-dimensional MRI, respectively) and 6-month PFS (26%).
Furthermore, among 15 patients receiving corticosteroids
on study entry, the dose was reduced (n = 10) or discon-
tinued (n = 5).
Conclusions
Maintenance of QoL in patients with high-grade glioma is
an important endpoint during treatment, and more so for
GBM because of the particularly poor prognosis with short
life expectancy at this stage of the disease. However,
reliable serial measurement of QoL in patients with high-
grade glioma is notoriously difﬁcult, relating to many
factors but particularly dropout bias or inability to repeat-
edly complete complex forms. It would appear that there is
a progressive decrease in QoL during the course of high-
grade glioma that substantially accelerates once the disease
relapses. This is also expressed as deterioration peaks dri-
ven by the administered therapies (e.g., radiotherapy) or by
the exacerbation of accompanying syndromes (e.g., brain
edema, neurological symptoms, psychiatric disturbances).
It has proven difﬁcult to identify new therapies that
extend OS and PFS in patients with recurrent GBM after
failure of previous therapy. Most alternative cytotoxic
chemotherapeutic agents do not seem to signiﬁcantly
impact response or survival, yet may produce adverse
effects that have a likely negative impact on QoL. How-
ever, among the new biological agents, bevacizumab has
been shown to induce a clinically meaningful proportion of
durable responses among patients with an acceptable safety
proﬁle. Furthermore, data are emerging that bevacizumab
induces improvement or preservation of neurocognitive
function, suggestive of QoL improvement, in the majority
of poor-prognosis patients who would otherwise be
expected to show a sudden, rapid deterioration in QoL.
Further studies are underway to conﬁrm these ﬁndings and
better understand the natural history of the QoL of these
patients.
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Table 1 Neurocognitive changes in patients with recurrent glio-
blastoma receiving single-agent bevacizumab in the BRAIN study
Assessment Change in performance at week 6
relative to baseline (per Reliable
Change Index)
Improved
(%)
Declined
(%)
Stable
(%)
HVLT-R total recall (n = 74) 16 18 66
HVLT-R delayed recall
(n = 70)
14 16 70
HVLT-R delayed recognition
(n = 69)
22 19 59
TMTA (n = 73) 23 11 66
TMTB (n = 65) 28 11 62
COWA (n = 70) 3 0 97
HVLT-R Hopkins Verbal Learning Test-Revised, TMTA Trail Making
Tests part A, TMTB Trail Making Test part B, COWA Controlled Oral
Word Association test
Table 2 Stabilization or improvement in neurocognitive function in
patients with recurrent glioblastoma receiving single-agent bev-
acizumab in the BRAIN study
Stable/improved
neurocognitive
function on all tests
n (%)
Deterioration in
neurocognitive function
in at least one test n (%)
Responders at
time of IRF
response
(n = 24)
18 (75%) 6 (25%)
PFS[6 months
at week 24
(n = 27)
a
19 (70%) 8 (30%)
Patients at time
of investigator
PD (n = 49)
b
15 (31%) 34 (69%)
IRF independent radiology facility, PFS progression-free survival,
PD progressive disease
a Two patients had missing neurocognitive data and were dropped
from the analysis
b Eight patients had missing neurocognitive data and were dropped
from the analysis
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